Drug Importation Debate: Ilisa Bernstein on the Global Pill

RealPharma: Conversations with Pharma Pathfinders

Summary

Ilisa Bernstein, a senior Vice President at the American Pharmacists Association, discusses the history and current landscape of drug importation policies with a focus on Florida's program.

Safety concerns, supply chain issues, and intellectual property rights are key considerations. The impact on the Canadian drug supply and the transparency of imported drugs for consumers are also discussed. Manufacturer concerns regarding rebates and discounts, as well as potential oversupply and export restrictions, are highlighted. The conversation explores the complexities and concerns surrounding drug importation programs. It discusses the mechanisms that manufacturers may use to control drug importation, such as restricting volume or increasing prices. The potential impact on the drug supply in Canada and the need for policies to protect it are also examined. The logistical challenges at the border and the vulnerabilities in the drug supply chain are highlighted. The importance of maintaining patient confidence in drug quality and the risks associated with personal drug importation are discussed. The conversation concludes by considering alternative solutions to lower drug prices and the inspiration drawn from historical figures.

Chapters

00:00 Introduction of Ilisa Bernstein

01:19 Background on Drug Importation

08:21 Safety Concerns

10:04 Supply Chain and Drug Source

14:58 Transparency and IP Issues

20:57 Consumer Transparency and NDC Numbers

21:10 Intellectual Property Concerns

22:59 Challenges and Points of Contention

25:12 Manufacturer Concerns: Rebates and Discounts

28:06 Oversupply and Export Restrictions

29:09 Mechanisms to Control Drug Importation

30:39 Policies to Protect Drug Supply in Canada

31:12 Logistical Challenges at the Border

33:07 Vulnerabilities in the Drug Supply Chain

35:03 Maintaining Patient Confidence in Drug Quality

36:31 Risks Before the Border

38:01 Complexities and Concerns for Community Pharmacists

41:31 The Future of Drug Importation Programs

44:00 The Motivation Behind Drug Importation Programs

46:01 Exploring Other Solutions to Lower Drug Prices

48:19 The Illegality of Personal Drug Importation

49:05 Balancing Cost Savings and Patient Safety

50:02 Inspiration from Historical Figures

Resources:

• Ilisa Bernstein

• American Pharmacists Association

• The Partnership for Safe Medicines